Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2845785 | 1.00 | HPGD (0.46) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL17181323 | 1.00 | HPGD (0.46) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL10177807 | 1.00 | HPGD (0.46) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL17978825 | 1.00 | HPGD (0.46) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL31350781 | 0.88 | HPGD (0.46) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL376676 | 0.88 | HPGD (0.46) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL21188762 | 0.88 | HPGD (0.46) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL17438284 | 0.88 | HPGD (0.46) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL15749167 | 0.88 | HPGD (0.46) | HPGDRECQLEPHX1ALDH1A1MAPT | |
| SCHEMBL9773777 | 0.86 | NR1H2 (0.46) | HPGDRECQLEPHX1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119654314-A | Heterocyclic amide and urea compounds as JAK2 inhibitors | 艾捷斯治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| US-12157746-B2 | Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240351999-A1 | PYRROLYLACYLPIPERIDYLAMINE COMPOUND AND USE THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2024-10-24 | — | — | US | disclosed |
| US-RE50082-E1 | (5,6-dihydro)pyrimido[4,5-e]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2024-08-20 | — | — | US | disclosed |
| US-20240140919-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2024-05-02 | — | — | US | disclosed |
| US-20240116892-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2024-04-11 | — | — | US | disclosed |
| CN-117843552-A | Resolution method of cis-4-amino-3-methoxypiperidine-1-formate optical isomer | 中国医学科学院药物研究所 | 2024-04-09 | — | — | CN | disclosed |
| CN-115466246-B | Pyrrole amide piperidine amine compound and application thereof | 中国医学科学院药物研究所 | 2024-02-06 | — | — | CN | disclosed |
| CN-117343085-A | Psoralen derivative and application thereof | 中国人民解放军海军军医大学 | 2024-01-05 | — | — | CN | disclosed |
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20110294777-A1 | BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-12-01 | — | — | US | disclosed |
| EP-2379525-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | Boehringer Ingelheim International GmbH (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-8003785-B2 | Halo-substituted pyrimidodiazepines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2303889-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226322-A1 | IMIDAZOLE CARBONYL COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-09-08 | — | — | EP | disclosed |
| WO-2010070032-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-24 | — | — | WO | disclosed |
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| WO-2009153197-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009091856-A2 | BETA-LACTAMASE INHIBITORS | MERCK & CO., INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294777-A1 | BETA-LACTAMASE INHIBITORS | MGAM, RPIA, LBR | HPGD 813/4885RECQL 406/4885EPHX1 3302/4885 |
| US-20240116892-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | JAK2, JAK1, JAK3 | HPGD 1772/4885RECQL 2274/4885EPHX1 4239/4885 |
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | HPGD 3667/4885RECQL 980/4885EPHX1 3999/4885 |
| US-20240351999-A1 | PYRROLYLACYLPIPERIDYLAMINE COMPOUND AND USE THEREOF | AADAT, PKD1, PCTP | HPGD 2004/4885RECQL 2692/4885EPHX1 4470/4885 |
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | HPGD 1751/4885RECQL 80/4885EPHX1 4397/4885 |
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | HPGD 414/4885RECQL 1292/4885EPHX1 1891/4885 |
| US-12157746-B2 | Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | HLA-DRB1, SSB, REN | HPGD 1987/4885RECQL 57/4885EPHX1 1467/4885 |
| US-20240140919-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | HPGD 3667/4885RECQL 980/4885EPHX1 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.